Targeted Oncology

Choosing First-Line Therapy Among Four FDA-Approved HER2-Directed Options: Route, Efficacy, and Patient Fit

First-line treatment selection in HER2-mutant NSCLC balances route of administration, efficacy data by mutation subtype, and ...
ascopubs.org

First-line treatment of EGFR mutation adenosquamous carcinoma of the lung with aumolertinib: A multicenter, single-arm, prospective study (ARISE Study).

Population pharmacokinetics of trastuzumab deruxtecan (T-DXd) in subjects with HER2-mutant and HER2-overexpressing non-small cell lung cancer (NSCLC). This is an ASCO Meeting Abstract from the 2024 ...

The sNDA for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First‑Line Treatment for PD-L1-positive NSCLC Accepted for Review by NMPA

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company") announced that the sNDA (the "Application") for the Company's TROP2 ADC sacituzumab tirumotecan (sac-TMT, also ...
Healio

Pulsed field ablation as first-line treatment superior to drug therapy in persistent AF

In patients with persistent atrial fibrillation, those receiving pulsed field ablation as first-line therapy had less risk ...
MedPage Today

A New Standard in First-Line Therapy for HER2-Positive Breast Cancer?

In the DESTINY-Breast09 trial, presented at this year's American Society of Clinical Oncology (ASCO) annual meeting, first-line trastuzumab deruxtecan (T-DXd; Enhertu) combined with pertuzumab ...
The American Journal of Managed Care

Navigating First-Line Therapy Guidelines and Treatment Considerations in High-Risk Cytogenetics

Panelists discuss how NCCN guidelines are expected to incorporate quadruplet-based regimens as reasonable treatment approaches for transplant-ineligible patients, while emphasizing the need for ...
ascopubs.org

Comparative analysis of first-line therapy with fruquintinib plus chemotherapy versus standard therapy in advanced metastatic colorectal cancer (mCRC): A prospective cohort ...

Prognostic genomic signatures in patients with RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) from the phase III study of first-line FOLFIRI/cetuximab versus FOLFIRI/cetuximab ...
Healio

First-line immunotherapy underutilized in kidney cancer; ‘different mechanisms’ needed

Please provide your email address to receive an email when new articles are posted on . Immune checkpoint inhibitor-based combinations are the preferred first-line therapy for metastatic clear cell ...